Association of p16 as Prognostic Factors for Oropharyngeal Cancer: Evaluation of p16 in 1470 Patients for a 16 Year Study in Northeast China

Table 3

The relationship between p16 overexpression, HPV status, and clinical parameters of patients.

Variable	p16-IHC			HPV DNA-PCR
	Positive	Negative		Positive	Negative
	Patient characteristics
Age at diagnosis, years
⩽45	12	73	0.0034	11	74	0.0012
46–55	43	426	0.00004	41	428	0.000058
56–65	16	608	0.00002	16	608	0.000056
⩾66	10	282	0.081	10	282	0.109
Sex
Male	72	1095	0.029	69	1098	0.0417
Female	9	294	0.041	9	294	0.041
History of smoking
Yes (current/former)	72	1224	0.835	69	1227	0.933
No (never)	9	165	0.833	9	165	0.833
History of alcohol
Yes (current/former)	57	833	0.062	54	836	0.106
No (never)	24	556	0.082	24	556	0.08
Treatment
Surgery alone	57	1200	0.00006	55	1202	0.00011
Surgery + radiotherapy	24	181	0.00003	23	182	0.000047
Surgery + chemoradiotherapy	0	8	0.49	0	8	0.501
Event after initial CRT
Residual tumor (PD, SD, and PR)	21	265	0.13	21	265	0.086
CR followed by recurrence/metastasis	35	406	0.007	33	408	0.014
Durable CR	25	718	0.0003	24	719	0.00033